We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $3.61B
1-Year Est. Return 203.3%
This Fund
S&P 500
This Quarter Est. Return
+18.65%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$160M
Cap. Flow
+$578K
Cap. Flow %
0.03%
Top 10 Hldgs %
48.49%
Holding
131
New
15
Increased
21
Reduced
19
Closed
21

Top Buys

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$23.3M
2
BCAX
Bicara Therapeutics
BCAX
+$23.2M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$21.1M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.7M
5
AVBP icon
ArriVent BioPharma
AVBP
+$14.5M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$64.3M
2
SLNO
Soleno Therapeutics
SLNO
+$19.5M
3
PRTA icon
Prothena Corp
PRTA
+$15.9M
4
SMMT icon
Summit Therapeutics
SMMT
+$13.4M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 90.42%
2 Technology 4.93%
3 Communication Services 2.51%
4 Consumer Discretionary 1.07%
5 Real Estate 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSM icon
51
TSMC
TSM
$2.18T
$6.91M 0.36%
30,500
+2,000
+7% +$371K
GOSS icon
52
Gossamer Bio
GOSS
$87M
$6.41M 0.33%
5,208,968
– –
CRM icon
53
Salesforce
CRM
$158B
$6.16M 0.32%
22,600
+8,000
+55% +$2.14M
COGT icon
54
Cogent Biosciences
COGT
$7.24B
$6.13M 0.32%
+854,379
New +$4.74M
RNAC icon
55
Cartesian Therapeutics
RNAC
$268M
$5.85M 0.3%
563,272
– –
VERA icon
56
Vera Therapeutics
VERA
$2.36B
$5.82M 0.3%
247,216
-500,000
-67% -$11.2M
ADBE icon
57
Adobe
ADBE
$105B
$5.82M 0.3%
15,051
-4,247
-22% -$1.64M
SION
58
Sionna Therapeutics
SION
$2.31B
$5.64M 0.29%
325,000
– –
PDD icon
59
Pinduoduo
PDD
$131B
$5.54M 0.29%
52,901
– –
SGMT icon
60
Sagimet Biosciences
SGMT
$559M
$5.52M 0.29%
724,771
– –
SYRE icon
61
Spyre Therapeutics
SYRE
$9.25B
$5.52M 0.29%
368,598
– –
PCRX icon
62
Pacira BioSciences
PCRX
$997M
$5.38M 0.28%
+225,000
New +$5.67M
NOW icon
63
ServiceNow
NOW
$129B
$5.27M 0.27%
25,630
-20,000
-44% -$3.77M
KRRO icon
64
Korro Bio
KRRO
$195M
$5.23M 0.27%
418,833
– –
DDOG icon
65
Datadog
DDOG
$83.3B
$5.16M 0.27%
38,425
-9,000
-19% -$996K
AGEN
66
Agenus
AGEN
$290M
$4.86M 0.25%
1,064,250
+564,250
+113% +$1.95M
FROG icon
67
JFrog
FROG
$10.8B
$4.7M 0.24%
107,116
-24,500
-19% -$931K
RAPP
68
Rapport Therapeutics
RAPP
$2.18B
$4.3M 0.22%
378,469
– –
TIL icon
69
Instil Bio
TIL
$50.3M
$4.25M 0.22%
203,933
– –
DT icon
70
Dynatrace
DT
$14.2B
$4.15M 0.21%
75,229
-12,500
-14% -$626K
WHWK
71
Whitehawk Therapeutics
WHWK
$235M
$3.89M 0.2%
2,082,000
– –
EDU icon
72
New Oriental
EDU
$8.98B
$3.88M 0.2%
72,000
-7,500
-9% -$356K
IGMS
73
DELISTED
IGM Biosciences
IGMS
$3.65M 0.19%
3,255,826
– –
FHTX icon
74
Foghorn Therapeutics
FHTX
$360M
$3.39M 0.18%
720,720
– –
VIGL
75
DELISTED
Vigil Neuroscience
VIGL
$3.27M 0.17%
411,191
-1,555,873
-79% -$6.97M
1 2
3
4 5

Similar funds

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Siren LLC's Q2 2025 Portfolio in Review

As of Q2 2025, Siren LLC held 131 positions worth $1.93B, up 9% from $1.77B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Siren LLC's Q2 2025 filing shows 15 new, 21 increased, 19 reduced and 21 closed positions. Its largest new stake was MoonLake Immunotherapeutics: 508,267 shares worth $24M. The largest sale was Blueprint Medicines, an estimated $64.3M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier, followed by Technology and Communication Services.

  • Siren LLC's largest Q2 2025 buy was MoonLake Immunotherapeutics: 508,267 shares worth $24M.
  • Siren LLC added most to Dyne Therapeutics in Q2 2025, an estimated $23.3M increase.
  • Siren LLC's biggest Q2 2025 reduction was Soleno Therapeutics, cutting an estimated $19.5M.
  • Siren LLC fully exited Blueprint Medicines in Q2 2025, selling an estimated $64.3M.
  • Siren LLC's ten largest holdings make up 48% of its $1.93B portfolio in Q2 2025.
  • Siren LLC opened 15 new positions and closed 21 in Q2 2025.
  • Siren LLC's portfolio value rose 9% quarter-over-quarter to $1.93B.

Based on Siren LLC's 13F filing for Q2 2025, filed 13 Aug 2025.